Acknowledging our funders

All researchers who conduct research supported by the Cancer Research UK Cambridge Centre must acknowledge the appropriate funders in their research publications and presentations, and where possible in all media communications (including written and spoken interviews with journalists).

Even if your research is not directly funded by the Centre, there may be indirect support. The Centre supports many research and operational staff based in the University and Cambridge University Hospitals NHS Foundation Trust, as well as contributing to core infrastructure such as the Cancer Molecular Diagnostics Laboratory (CMDL), Cambridge Cancer Trials Centre (CCTC), and Cambridge Breast Cancer Research Unit (CBCRU).

The Cancer Research UK Cambridge Centre is funded primarily by a major centre award from Cancer Research UK. We receive additional funding from Cancer Research UK for the International Alliance for Cancer Early Detection (ACED), the CRUK radiation research network (RadNet), the CRUK Clinical Academic Training Programme, the CRUK Children’s Brain Tumour Centre of Excellence and the Cambridge Experimental Cancer Medicine Centre (ECMC).

We also receive substantial funding support from the National Institute for Health and Care Research (NIHR) through the Cambridge Biomedical Research Centre Cancer Theme which supports infrastructure across the Cambridge Biomedical Campus including the Cancer Molecular Diagnostics Laboratory (CMDL), Cambridge Cancer Trials Centre (CCTC), sample collection and the Human Research Tissue Bank, as well as the departments and institutes involved in translational research.

The Mark Foundation Institute for Integrated Cancer Medicine is funded by The Mark Foundation for Cancer Research.

Please use the following wording (in bold) when acknowledging funding for your research:

Cancer Research UK Cambridge Centre

This work was supported by the Cancer Research UK Cambridge Centre [CTRQQR-2021\100012].

NB: For research undertaken and funded before March 2022, please use:
This work was supported by the Cancer Research UK Cambridge Centre [C9685/A25117] 

Cancer Molecular Diagnostics Lab

This work was supported by the Cancer Molecular Diagnostics Lab at the Cancer Research UK Cambridge Centre [CTRQQR-2021\100012].

International Alliance for Cancer Early Detection (ACED)

This work was supported by the International Alliance for Cancer Early Detection, a partnership between Cancer Research UK [C14478/A27855], Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London and the University of Manchester.

Cancer Research UK RadNet Cambridge

This work was supported by Cancer Research UK RadNet Cambridge [C17918/A28870].


Cancer Research UK Clinical Academic Training Programme

[insert name] is funded by the Cancer Research UK Clinical Academic Training Programme.


Cambridge Experimental Cancer Medicine Centre

This work was supported by the Cambridge Experimental Cancer Medicine Centre (ECMC) [C96/A25177/RG86728].

NIHR Cambridge Biomedical Research Centre

Please make sure that you acknowledge the BRC in all your qualifying publications as indicated in the following eligibility criteria: If your research has taken place on the Cambridge Biomedical Campus and involved human participants, samples or data, then the NIHR Cambridge BRC have either directly or indirectly supported it and you are contractually obliged to acknowledge NIHR funding. When submitting papers, please ensure you use the following acknowledgement in your manuscript, in the Acknowledgements section, unless you have a very clear reason why the BRC is not involved:

This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014*). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. 

*BRC-1215-20014 is the infrastructure award number from April 2017-December 2022. The award numbers are used in search engine audits as part of the NIHR reporting process and must be included.

Mark Foundation Institute for Integrated Cancer Medicine

All research supported by the Mark Foundation Institute for Integrated Cancer Medicine must include one of the following acknowledgements in scientific publications. Please inform Ellie Wolmark (Eleanor.wolmark@cruk.cam.ac.uk) MFICM Communications/Programme Manager when your manuscript has been submitted as we are required to send all draft publications to The Mark Foundation for Cancer Research for review before publication.

Short acknowledgement statement:
This work was supported by The Mark Foundation for Cancer Research [RG95043] and the Cancer Research UK Cambridge Centre [CTRQQR-2021\100012].

OR Long acknowledgment statement:
This work was supported by The Mark Foundation Institute for Integrated Cancer Medicine (MFICM). MFICM is hosted at the University of Cambridge, with funding from The Mark Foundation for Cancer Research (NY, USA) [RG95043] and the Cancer Research UK Cambridge Centre (UK) [CTRQQR-2021\100012].

Cancer Research UK Children’s Brain Tumour Centre of Excellence

All research supported by the CRUK Children’s Brain Tumour Centre of Excellence, which is co-hosted by Cambridge and the Institute of Cancer Research, must include one of the following acknowledgements in scientific publications.

This work was supported by The CRUK Children’s Brain Tumour Centre of Excellence (C9685/A26398/RG93685).

OR Long acknowledgment statement:

This work was supported by The CRUK Children’s Brain Tumour Centre of Excellence (CRUK-CBTCE). The CRUK-CBTCE is hosted at the University of Cambridge and The Institute of Cancer Research, London and funded by Cancer Research UK [C9685/A26398/RG93685].